Banner - NPPA Connect
|Articles|May 1, 2005

Simple approach yields best results

New Orleans — Facial reconstruction does not have to be as complicated a procedure as it might sound, according to Ken K. Lee, M.D., who presented a seminar on facial reconstruction at the 63rd Annual Meeting of the American Academy of Dermatology (AAD) here.

New Orleans - Facial reconstruction does not have to be as complicated a procedure as it might sound, according to Ken K. Lee, M.D., who presented a seminar on facial reconstruction at the 63rd Annual Meeting of the American Academy of Dermatology (AAD) here.

Linear closures for the nose Dr. Lee places emphasis on several facial reconstruction procedures, beginning with linear closures for the nose.

He adds that surgeons should be wary of alar retraction and internal valve compromise if the closure is too tight.

"The surgeon should close the superior and inferior aspects of the defect in similar fashion to linear closure," Dr. Lee says. "A superior dog ear, shaped in a fusiform elliptical configuration, should be used as the graft. One may need to thin the graft more than usual and set it in slightly."

"In this procedure, one should try to keep incisions on the cutaneous lip in a vertical/radial direction, and shouldn't be afraid to cross the vermilion border," he says. "The surgeon should remove as little or as much muscle as needed to settle down the dog ear and extend the incision through the dry vermilion so that an abrupt interruption is not seen. The vermilion border should then be carefully re-approximated."

Related to this article

Day 3 Recap: Fall Clinical 2026
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Day 2 Recap: Fall Clinical 2026
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.